When to Consider an Allograft in Chronic Myeloid Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Eduardo Olavarria (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

BCR-ABL Negative CML-Like Disorder
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Nick Cross (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Novel Therapeutic Options in CML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Michael Deininger (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Treatment Free Remission for Chronic Myeloid Leukemia in 2017
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Timothy P. Hughes (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

MPN: Next Questions: Potential New Targets for MPN beside JAK2
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ann Mullally (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Case Study: Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Karen Ballen (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Therapy of Myelofibrosis: Where We Are and What Next
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Srdan Verstovsek (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Understanding New WHO Classification of MPNs
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Francesco Passamonti, Barbara Mora, Margherita Maffioli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

State of the Art Update: Molecular Genetics of MPN
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ann Mullally (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Emerging Therapies and Clinical Challenges in Chronic Myelomonocytic Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Eric Padron (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Should Molecular Genetics Guide the Decision for Allogeneic Transplant? - Con
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Guillermo F. Sanz (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Myelodysplastic Syndromes Debate: Should Molecular Genetics Guide the Decision for Allogeneic Transplant - Pro
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Corey Cutler (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The NLRP3 Inflammasome as a Driver of the MDS Phenotype
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Alan List (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Clonal Hematopoiesis and MDS Risk
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Koichi Takahashi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

CAR T-Cell Therapies: Overcoming the Challenges and New Strategies
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Partow Kebriaei (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

T-cell ALL: New Insights to the Biology
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Jan Cools (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Use of MRD for Selection of Post Remission Therapy in Adult All Management
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Josep-Maria Ribera (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Monoclonal Antibodies in Acute Lymphocytic Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elias Jabbour, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Progress in the Study of Pediatric ALL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ching-Hon Pui, St. Jude (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

New Discoveries in Biology and Molecular Markers
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Charles G. Mullighan (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elias Jabbour, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Breast Implant-Associated Anaplastic Large Cell Lymphoma: An Update
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Roberto N. Miranda (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Advances in the Pathology of High Grade B Cell Lymphomas
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Shaoying Li, Pei Lin, Carlos Bueso-Ramos, L. Jeffrey Medeiros (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The Impact of the Microbiome on Infectious Outcomes in Patients with Hematologic Malignancy
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Samuel A. Shelburne (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The Impact of the Microbiome on Outcomes of Stem Cell Transplant
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Robert Jenq (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Based Approaches in AML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Naval Daver, Guillermo Garcia-Manero, Pam Sharma, James Allison, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Co-Stimulatory Regulation of CAR T Cell Function
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Justin C. Boucher, Marco L. Davila (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Single Cell Analysis for Drug Discovery and Development
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): James R. Heath (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Next Generation Chimeric Antigen Receptor (CAR) T Cells
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Renier Brentjens (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Other Cancers in CLL, a Common Problem
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Lorenzo Falchi, Alessandra Ferrajoli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Is MRD Useful in CLL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Paolo Ghia (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Management of Lower Risk Non-del(5q) MDS
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Valeria Santini (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

What Can Your Radiation Oncologist Do Today: Technology at Your Service to Maximize the Therapeutic Ratio
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Bouthaina Dabaja (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Myelofibrosis with Cytopenias
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Prithviraj Bose (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Polycythemia Vera: When to Move from Hydroxyurea to Second Line Therapy
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Brady L. Stein (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Management of Post ET/PV MF: Different from Primary MF
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Francesco Passamonti, Barbara Mora, Margherita Maffioli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Models in AML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elihu Estey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

How and When to Use FLT3 Inhibitors
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Mark Levis (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Acute Myeloid Leukemia in the Older Patient: Science or Craft?
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Laura C. Michaelis (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Application of NSG in Newly Diagnosed AML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Guido G. Marcucci (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Update on Transplant in ALL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Mark R. Litzow (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Farhad Ravandi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Clinical Applications and Pitfalls of MRD in ALL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Dieter Hoelzer (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Frontline Therapy in Chronic Myeloid Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Molecular Monitoring in the Treatment Free Remission Era
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Nick Cross (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Treatment Free Remission – The U.S Perspective
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Charles A. Schiffer (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Targeted Therapy in AML: Something for Everyone?
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Richard Stone (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

CML Management in 2017
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Michael J. Mauro (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome
Publication date: August 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 8 Author(s): Catherine Tang, Julian Lindsay, Anthony Gill, Ian Kerridge (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 27, 2017 Category: Cancer & Oncology Source Type: research

Daunorubicin 90 mg/m2 in Acute Myeloid Leukemia Induction: Increased Toxicity in Young  Patients
Conclusion These data indicate that 90 mg/m2 of daunorubicin increased the toxicity compared with lower doses. Micro-Abstract We evaluated the outcome of AML patients treated with daunorubicin 90 mg/m2. Higher rates of invasive fungal disease, antifungal therapy, creatinine elevation, gastrointestinal toxicity and intensive care unit admissions were observed with increased anthracycline dose. The daunorubicin induction dose should be greater than 45 mg/m2 but escalation to 90 mg/m2 seems excessive. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 27, 2017 Category: Cancer & Oncology Source Type: research